Purpose: Exploring efficacy and safety for first single dose of rituximab(RTX) in children with steroid dependent-minimal change nephrotic syndrome(SD-MCNS) by retrospective analysis in two years after RTX and established the model of prediction for relapsing. Methods: Children with SD-MCNS, admitted in our hospital and received single dose of RTX(375mg/m2) by first time from Oct 2011 to Dec 2018, were included. They were followed by 24 months. The clinical and laboratory data before and after RTX were collected and analyzed. Results: 77 patients (M/F: 51/26) were included. The median age was 8.17 years old. The median dependent dosage of steroids was 7.87mg/m2·d. The efficacy for the first single dose of RTX in children with SD-MCNS was 90.91%(70/77), 60 patients (77.9%) for complete remission and 10(13.0%) for partial remission. The relapse rate was 78.3%. There were no severe side effects. Age using RTX, dependent dosage of steroids and CD4+ level before RTX had relationship with efficacy of RTX (B=0.390, -0.091, 0.134, P<0.05). Sex, ageing using RTX, IgE before RTX, WBC and CD3+ when stopping steroids were related to relapsing (B=-1.485, -0.373, 1.278, -0.417, 0.135, P<0.05). The model of prediction for relapsing after RTX in children with SD-MCNS was established.Conclusion: Single dose of RTX is efficiency and safe in children with SD-MCNS, but with high recurrence rate. Patients with older age using RTX, or smaller dependent-dosage of steroids, or higher CD4+ have better efficacy for RTX. Male younger patients with higher IgE relapse more easily.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.